6 completed, 1 not yet recruiting, 1 unknown, 1 withdrawn. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Chronic Idiopathic Urticaria: new trials by email Literature Review of Chronic Idiopathic Urticaria trials Research Report on Chronic Idiopathic Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) THB335 Lower Dose, THB335 Higher Dose, Placebo - Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria | Phase 2 | Not yet recruiting | Calixis Inc. | 81 | 2026-09-01 | 2026-08-17 |
| Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Povorcitinib, Placebo - Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Completed | Incyte Corporation | 136 | 2023-07-31 | 2026-03-12 |
| A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases KPL-716, Placebo - Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus | Phase 2 | Completed | Genentech, Inc. | 58 | 2019-05-29 | 2025-03-18 |
| Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines AZD1981, Placebo - Chronic Idiopathic Urticaria | Phase 2 | Completed | Johns Hopkins University | 38 | 2014-01-01 | 2017-07-12 |
| Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Omalizumab (Xolair), Placebo - Chronic Urticaria, Chronic Idiopathic Urticaria | Phase 2 / Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 30 | 2012-09-01 | 2014-04-15 |
| Efficacy Study of Canakinumab to Treat Urticaria Canakinumab, Placebo - Chronic Idiopathic Urticaria | Phase 2 | Unknown | University of Zurich | 20 | 2012-06-01 | 2016-09-27 |
| Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment IGE025, placebo - Chronic Idiopathic Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2012-04-01 | 2015-03-31 |
| Etanercept for the Treatment of Chronic Urticaria etanercept, placebo - Chronic Idiopathic Urticaria | Phase 2 / Phase 3 | Withdrawn | University of Utah | 2010-12-01 | 2015-06-02 | |
| A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) omalizumab, placebo, H1 antihistamines - Chronic Idiopathic Urticaria | Phase 2 | Completed | Genentech, Inc. | 90 | 2009-03-01 | 2017-07-11 |
Chronic Urticaria (9) · Urticaria (3) · Pruritus (2) · Angioedema (1) · Lichen Planus (1) · Neurodermatitis (1)
Chronic Disease (9) · Disease Attributes (9) · Hypersensitivity (9) · Hypersensitivity, Immediate (9) · Immune System Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Skin Diseases (9) · Skin Diseases, Vascular (9) · Skin and Connective Tissue Diseases (9) · Urticaria (6) · Signs and Symptoms (2) · Skin Manifestations (2) · Cardiovascular Diseases (1) · Dermatitis (1)
Omalizumab (3) · AZD1981 (1) · Diphenhydramine (1) · Etanercept (1) · canakinumab (1)
Genentech, Inc. (2) · Calixis Inc. (1) · Incyte Corporation (1) · Insel Gruppe AG, University Hospital Bern (1) · Johns Hopkins University (1) · Novartis Pharmaceuticals (1) · University of Utah (1) · University of Zurich (1)
United States (4) · Germany (2) · Switzerland (2) · Poland (1)
Christopher Hull, MD (1) · Karin Rosen, M.D., Ph.D. (1) · Oliver Hausmann (1) · Peter Schmid-Grendelmeier, Prof MD (1) · Sarbjit S Saini, MD (1)